Four Biotech Names with Major Market Potential: Michael Higgins
The Life Sciences Report: Michael, we live with a regulatory process in drug development that lasts for years. It seems to consume investors as we watch a molecule go through the pipeline. Do you . . . → Read More: Four Biotech Names with Major Market Potential: Michael Higgins Similar posts: Chen Lin’s Key to Huge Biotech Profits: Make It Personal The Life Sciences Report: Chen, we know you as a... Special Report Reveals Biotech Stock Drivers: Michael Hay The Life Sciences Report: From a share price perspective, what’s... Special Report from the ADA: William Plovanic Identifies Companies with Promising Diabetes Solutions, Prospects The Life Sciences Report: You recently attended the 72nd Annual...
The Life Sciences Report: Michael, we live with a regulatory process in drug development that lasts for years. It seems to consume investors as we watch a molecule go through the pipeline. Do you think investors place too much emphasis on pivotal trial data, advisory committee votes and Prescription Drug User Fee Act (PDUFA) outcomes when, in some cases, a product’s market potential might not even merit that amount of due diligence?
Michael Higgins: Yes. I think you’re dead on. The clinical and regulatory boxes have to be checked, of course, but quite often investors haven’t done … [visit site to read more]
- Chen Lin’s Key to Huge Biotech Profits: Make It Personal The Life Sciences Report: Chen, we know you as a...
- Special Report Reveals Biotech Stock Drivers: Michael Hay The Life Sciences Report: From a share price perspective, what’s...
- Special Report from the ADA: William Plovanic Identifies Companies with Promising Diabetes Solutions, Prospects The Life Sciences Report: You recently attended the 72nd Annual...